Clinical Trial

Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

Study acronym: OV-PRIME-R
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I clinical trial that will investigate the safety and tolerability of combining the modified vaccinia virus BT-001 with systemic pembrolizumab in patients with localised pMMR rectal cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-30.
Trial Details
NCT Number NCT07687875
Lead Sponsor Henry Smith
Collaborators: Transgene, Rigshospitalet, Denmark
Conditions Rectal Cancer Patients
Enrollment 20 participants
Start Date 2026-06-17
Primary Completion 2028-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10